Recently Published Independent Research Study Detects Gene Variation In Non-Small Cell Lung Cancer Using The Sequenom Massarray® Research Use System

SAN DIEGO, May 29, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported on a recently released publication in which the Sequenom MassARRAY® System (for research use only) was used in a groundbreaking independent study that detected the transforming fusion gene EML4/ALK in non-small cell lung cancer. The study was conducted by researchers at Kinki University in Japan and appears in the May online issue of The Journal of Thoracic Oncology. The full results of the study can be found online at: http://journals.lww.com/jto/Abstract/2012/05000/A_Novel_Mass_Spectrometry_Based_Assay_for.20.aspx. 

The research study describes an assay which detects the transforming fusion gene echinoderm microtubule-associated protein-like 4 (EML4) anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Current research methods have limitations in terms of detecting different variants, and this study demonstrates the successful detection of nine EML4-ALK variants in total RNA obtained from formalin-fixed, paraffin-embedded (FFPE) specimens of NSCLC tissue.

As stated in the paper, "Our assay is able to distinguish between the different EML4-ALK variants in a small amount of formalin-fixed, paraffin embedded NSCLC tissue and it should prove to be a useful tool for the detection of EML4-ALK variants in testing for this fusion gene," said Kazuto Nishio, MD, Ph.D., Lead Author, Kinki University.

The EML4-ALK translocation occurs in five to 10 percent of lung cancer patients. Crizotinib, a tyrosine kinase activity inhibitor of ALK and MET, has been shown to be effective for the treatment of lung cancer patients harboring this translocation. In contrast to dual-color split-signal FISH analysis that is commonly used for screening ALK rearrangement or real-time PCR assays, this assay, utilizing the MassARRAY System, can detect nine EML4-ALK variants and wild-type ALK including 1, 2, 3a, 3b, 4, 5a, 5b, 6, and 7 transcripts.  

The research study was led by Dr. Kazuto Nishio, MD, PhD of the Departments of Genome Biology and Medical Oncology at the Kinki University in Osaka, Japan.  The Sequenom MassARRAY system is for research use only.  Not for use in diagnostic procedures.

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the use, benefits, and impact of the MassARRAY system and assays performed on the MassARRAY system, and Sequenom's commitment to improving healthcare through revolutionary genetic analysis solutions, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Sequenom's ability to develop and commercialize new technologies and products, particularly new technologies such as prenatal and other diagnostics and laboratory developed tests, Sequenom's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, ongoing litigation, including patent litigation, and other risks detailed from time to time in Sequenom, Inc.'s most recent Quarterly Report on Securities and Exchange Commission (SEC) Form 10-Q and Annual Report on SEC Form 10-K for 2011 and other documents subsequently filed with or furnished to the SEC. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom, Inc. undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.